Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BYEZZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Trastuzumab-C-9
|
|||||
| Synonyms |
Trastuzumab-C-9
Click to Show/Hide
|
|||||
| Organization |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.53
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
KR1020250002133A Trastuzumab-C-9 Linker
|
Linker Info | ||||
| Conjugate Type |
site-specific conjugation
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.021 nM | High HER2 expression (HER5 +++) | ||
| Method Description |
Trastuzumab-C-9 was tested in NCI-H358,80ul,18ᆬh
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.058 nM | High HER2 expression (HER6 +++) | ||
| Method Description |
Trastuzumab-C-9 was tested in NCI-H358,80ul,18ᆬh
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 136.77 nM | High HER2 expression (HER7 +++) | ||
| Method Description |
Trastuzumab-C-9 was tested in NCI-H358,80ul,18ᆬh
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 24.41 nM | High HER2 expression (HER8 +++) | ||
| Method Description |
Trastuzumab-C-9 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Emax (TNF-a) | 470.23 pg/mL | High HER2 expression (HER9 +++) | ||
| Method Description |
Trastuzumab-C-9 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||